[Multiple molecular-genetic defects in a woman with mixed hyperlipoproteinemia and early ischemic heart disease]

Terapevticheskii Arkhiv
|December 13, 2003
PubMed

Insights

Genetic analysis revealed that a combination of apolipoprotein E (apoE), LDLP receptor, and methylenetetrahydrofolate reductase (MTHFR) gene variations may contribute to early ischemic heart disease (IHD) in women.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Atherosclerosis Research

Background:

  • Mixed hyperlipoproteinemia (HLP) and early ischemic heart disease (IHD) present significant health challenges.
  • Genetic predisposition plays a crucial role in the development of cardiovascular diseases.
  • Understanding gene-environment interactions is key to personalized medicine.

Observation:

  • A female patient with mixed HLP and early IHD underwent genetic analysis.
  • The study examined polymorphisms in the apolipoprotein E (apoE), LDLP receptor, and methylenetetrahydrofolate reductase (MTHFR) genes.
  • The patient exhibited variations in all three genes: LDLP receptor A370T, MTHFR C677T, and apoE epsilon 2/epsilon 2 genotype.

Findings:

  • The proband presented with a unique combination of three genetic polymorphisms.
  • None of the examined relatives carried more than one of these specific gene variations.
  • This suggests a potential synergistic effect of these polymorphisms in disease development.

Implications:

  • The findings highlight the potential role of combined gene polymorphisms in the etiology of early-onset IHD in females.
  • This genetic insight could inform risk stratification and personalized prevention strategies for atherosclerosis.
  • Further research is warranted to elucidate the precise mechanisms linking these gene variants to IHD.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...